Gilead Sciences Inc.

GILD14 Dec 2024
Healthcare
$91.61
0.00 (-0.09%)
Lowest Today
$89.26
Highest Today
$91.83
Today’s Open
$91.61
Prev. Close
$91.61
52 Week High
$98.9
52 Week Low
$60.75
To Invest in Gilead Sciences Inc.

Gilead Sciences Inc.

Healthcare
GILD14 Dec 2024
0.00 (-0.09%)
1M
3M
6M
1Y
5Y
Low
$89.26
Day’s Range
High
$91.83
89.26
52 Week Low
$60.75
52-Week Range
52 Week High
$98.9
60.75
1 Day
-
1 Week
+0.3%
1 month return
-0.28%
3 month return
+11.55%
6 month return
+45.45%
1 Year return
+11.19%
3 Years return
+30.82%
5 Years return
+40.49%
10 Years return
-
Institutional Holdings
BlackRock Inc
9.68
Vanguard Group Inc
9.26
Capital World Investors
6.14
Capital Research Global Investors
4.96
State Street Corp
4.83
Vanguard Total Stock Mkt Idx Inv
3.15
Wellington Management Company LLP
2.78

Market Status

Fundamentals
Market Cap
115130.42 mln
PB Ratio
6.23
PE Ratio
1026.44
Enterprise Value
133342.04 mln
Total Assets
62125 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Organisation
Gilead Sciences Inc.
Employees
18000
Industry
Drug Manufacturers - General
CEO
Mr. Daniel P.  O'Day
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities